Clinical Trial Update: TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) trial is evaluating the combination of tumor-infiltrating lymphocytes (TILs) with a third-generation EGFR-TKI for patients with EGFR-TK…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Third-generation EGFR-TKI
• Tumor-infiltrating lymphocytes (TILs) (tumor-infiltrating lymphocytes)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: EGFR-TKI-resistant Non-Small Cell Lung Cancer | EARLY_Phase 1 | Status: NOT_YET_RECRUITING